

## LIST OF TABLES

S.NO.	Table Legends	PAGE NO
1.	Table 1.1.1: Different Types of Cancer mortality in developed countries	4
2.	Table 1.8.1: The key properties of drug-like compounds	40
3.	Table 3.2.1: The rule of 5 (Lipinski <i>et al.</i> , 1997)	71
4.	Table 3.2.2: Physicochemical/biopharmaceutical properties affecting the rate and extent of drug absorption from immediately release (1R) solid dosage form according to BCS (FDA 200)	72
5.	Table 3.2.3: The Biopharaceutics drug classification system	73
6.	Table 4.1.1: Best of 50 designed Pharmacophore Library of RESL analogs	102
7.	Table 4.1.2: Physico-chemical properties of best of fifty screened analogs, bold denoted compounds that are strictly following the rule of 5	105
8.	Table 4.1.3: ADME and toxicity prediction data of the designed molecules. (Bold analogs best screened analogs for further studies)	106
9.	Table 4.3.1: Experimental half maximal (50%) inhibitory concentration ( $IC_{50}$ ) of RESL and its analogs on U937	116
10.	Table 4.5.1: Docking energies of RESL analogs with NF- $\kappa$ B	131
11.	Table 4.6.1: Linear Interaction energies of RESL and its analogs with NF- $\kappa$ B Heterodimer	139
12.	Table 4.7.1: Hex Docking results of NF- $\kappa$ B RESL analogs with DNA	145